文献速递创伤与烧伤心脑血管急症重症综合管理与镇静镇痛

院前氨甲环酸给药不影响创伤性脑损伤患者入院时血栓弹力图

Tranexamic acid administration in the field does not affect admission thromboelastography after traumatic brain injury.
PubMed 文献 · J Trauma Acute Care Surg · 2020-01-01
一句话结论在大型院前TBI试验中,院前TXA虽降低D-二聚体和PAP水平,但入院及6小时后TEG纤溶指标与安慰剂无差异。

本研究基于一项安慰剂对照临床试验,纳入15岁及以上、GCS 3-12、收缩压≥90 mm Hg的TBI患者,院前随机接受安慰剂、TXA 1g弹丸+1g输注或TXA 2g弹丸+安慰剂输注。966例接受研究药物者中700例有入院及6小时实验室检测。结果显示各组TEG值(包括LY30)无统计学显著差异,常规凝血指标无差异;TXA组6小时D-二聚体低于安慰剂(p<0.001),入院及6小时PAP低于安慰剂(p<0.001;p=0.02),两种TXA方案间D-二聚体和PAP无差异。结论认为TXA虽降低纤溶标志物,但TEG未显示纤溶差异。

要点

  • 院前TXA两种方案(1g弹丸+1g输注;2g弹丸+安慰剂输注)与安慰剂相比,入院及6小时TEG值包括LY30均无统计学显著差异(p>0.05)。
  • TXA组6小时D-二聚体低于安慰剂组(p<0.001),入院及6小时PAP低于安慰剂组(p<0.001;p=0.02)。
  • 1g弹丸+1g输注方案与2g弹丸+安慰剂输注方案之间,D-二聚体和PAP均无差异。
  • PT、aPTT、INR、纤维蛋白原、凝血酶-抗凝血酶、tPA、PAI-1在各治疗组间均无差异。
  • 研究为诊断性试验,证据等级level III。

适用人群与场景

  • 年龄15岁及以上、GCS 3-12、收缩压≥90 mm Hg的TBI患者,院前场景随机接受研究药物。
  • 数据来自安慰剂对照临床试验,966例接受研究药物者中700例有入院及6小时实验室检测。

诊断标准与关键阈值

  • TBI诊断依据GCS 3-12;纳入需收缩压≥90 mm Hg。
  • 原文未提及TEG具体界值或纤溶诊断阈值。

处置流程与药物剂量

  • 院前随机分组:安慰剂弹丸/安慰剂输注;TXA 1g弹丸/1g TXA输注(bolus maintenance);TXA 2g弹丸/安慰剂输注(bolus only)。
  • 入院时及6小时后检测TEG及凝血指标包括PT、aPTT、INR、纤维蛋白原、D-二聚体、PAP、凝血酶-抗凝血酶、tPA、PAI-1。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:基于安慰剂对照临床试验的数据分析;样本量:966例接受研究药物,700例有入院及6小时实验室检测;人群:15岁及以上、GCS 3-12、收缩压≥90 mm Hg的TBI患者。
  • 干预与对照:院前安慰剂 vs TXA 1g弹丸+1g输注 vs TXA 2g弹丸+安慰剂输注。
  • 主要终点结果:各组TEG值包括LY30无统计学显著差异(p>0.05);PT、aPTT、INR、纤维蛋白原、凝血酶-抗凝血酶、tPA、PAI-1组间无差异。
  • 关键次要终点:TXA组6小时D-二聚体低于安慰剂(p<0.001);TXA组入院时PAP低于安慰剂(p<0.001),6小时PAP低于安慰剂(p=0.02);两种TXA方案间D-二聚体和PAP无差异。
  • 不良事件:原文未提及。

证据类型、等级与局限

  • 证据类型:诊断性试验(基于安慰剂对照临床试验的数据分析)。
  • 证据等级:level III。
  • 局限:原文未述局限性。

对床旁实践的改变

  • 院前TXA给药后,入院时及6小时TEG(包括LY30)未显示纤溶差异,临床不应仅依据TEG纤溶指标判断TXA效果。
  • TXA可降低D-二聚体和PAP水平,反映纤溶程度较低,但该变化与TEG结果不一致。
  • 两种TXA剂量方案(1g弹丸+1g输注 vs 2g弹丸+安慰剂输注)对D-二聚体和PAP的影响无差异。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: No Food and Drug Administration-approved medication improves outcomes following traumatic brain injury (TBI). A forthcoming clinical trial that evaluated the effects of two prehospital tranexamic acid (TXA) dosing strategies compared with placebo demonstrated no differences in thromboelastography (TEG) values. We proposed to explore the impact of TXA on markers of coagulation and fibrinolysis in patients with moderate to severe TBI.

METHODS: Data were extracted from a placebo-controlled clinical trial in which patients 15 years or older with TBI (Glasgow Coma Scale, 3-12) and systolic blood pressure of ≥90 mm Hg were randomized prehospital to receive placebo bolus/placebo infusion (placebo), 1 g of TXA bolus/1 g of TXA infusion (bolus maintenance), or 2 g of TXA bolus/placebo infusion (bolus only). Thromboelastography was performed, and coagulation measures including prothrombin time, activated partial thromboplastin time, international ratio, fibrinogen, D-dimer, plasmin-antiplasmin (PAP), thrombin antithrombin, tissue plasminogen activator, and plasminogen activator inhibitor 1 were quantified at admission and 6 hours later.

RESULTS: Of 966 patients receiving study drug, 700 had laboratory tests drawn at admission and 6 hours later. There were no statistically significant differences in TEG values, including LY30, between groups (p > 0.05). No differences between prothrombin time, activated partial thromboplastin time, international ratio, fibrinogen, thrombin antithrombin, tissue plasminogen activator, and plasminogen activator inhibitor 1 were demonstrated across treatment groups. Concentrations of D-dimer in TXA treatment groups were less than placebo at 6 hours (p < 0.001). Concentrations of PAP in TXA treatment groups were less than placebo on admission (p < 0.001) and 6 hours (p = 0.02). No differences in D-dimer and PAP were observed between bolus maintenance and bolus only.

CONCLUSION: While D-dimer and PAP levels reflect a lower degree of fibrinolysis following prehospital administration of TXA when compared with placebo in a large prehospital trial of patients with TBI, TEG obtained on admission and 6 hours later did not demonstrate any differences in fibrinolysis between the two TXA dosing regimens and placebo.

LEVEL OF EVIDENCE: Diagnostic test, level III.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Dixon AL, McCully BH, Rick EA, et al. Tranexamic acid administration in the field does not affect admission thromboelastography after traumatic brain injury. J Trauma Acute Care Surg. 2020. PMID: 33105308. doi:10.1097/TA.0000000000002932

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。